SHIM
ORKA icon

Stone House Investment Management’s Oruka Therapeutics ORKA Stock Holding History

Stone House Investment Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.8K Sell
902
-100
-10% -$6.66K 0.01% 170
2026
Q1 		$49.1K Buy
1,002
+2
+0.2% +$70 0.01% 181
2025
Q4 		$30.3K Hold
1,000
– – ﹤0.01% 211
2025
Q3 		$19.2K Buy
+1,000
New +$14.8K ﹤0.01% 230

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Stone House Investment Management's ORKA Position: Q2 2026 in Review

Stone House Investment Management reduced its Oruka Therapeutics (ORKA) stake by 10% in Q2 2026, selling an estimated $6.66K and leaving 902 shares worth $85.8K. The position accounts for 0.01% of the portfolio, ranked #170.

Stone House Investment Management first reported a position in ORKA in Q3 2025 and has held it in 4 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Stone House Investment Management held 902 shares of Oruka Therapeutics worth $85.8K as of Q2 2026.
  • Stone House Investment Management sold 100 Oruka Therapeutics shares in Q2 2026, an estimated $6.66K.
  • Oruka Therapeutics made up 0.01% of Stone House Investment Management's portfolio in Q2 2026, its #170 holding.
  • Stone House Investment Management first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.